Prevalence and risk factors of adverse drug events with dolutegravir-based regimens among Thai people living with HIV: a retrospective cohort study.

ABSTRACT:

Background

Dolutegravir (DTG)-based antiretroviral therapy (ART) is a preferred first-line treatment for HIV/AIDS, but concerns about adverse drug events (ADEs) persist. This study aimed to determine the prevalence of ADEs and identify associated independent risk factors among Thai people living with HIV (PLWH) on DTG-based regimens for at least one year.

Methods

This retrospective cohort study examined 1,270 Thai individuals living with HIV receiving a DTG/3TC/TDF regimen for ≥ 1 year at a secondary care hospital between 2021 and 2023. The primary outcome was any ADE (Grade ≥ 1) documented during the first 12 months of DTG therapy. Multivariate logistic regression, adjusted for confounders including sex, was used to identify independent predictors of ADEs.

Results

Am

SUBMITTER: Suriya S 

PROVIDER: S-EPMC12607200 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature